Skip to main content

Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California.
”We are very pleased to commence operations at the Obalon Center for Weight Loss,” said William Plovanic, President and Chief Financial Officer.  “We opened this direct channel to treat patients in order to improve outcomes and the access and affordability for patients with obesity seeking to lose weight with the Obalon Balloon System.  We invented, developed, manufactured, and now are facilitating delivery of this important therapy with the Obalon Balloon directly to patients.”The Obalon Center for Weight Loss is a medical facility staffed with physicians specializing in weight loss, nutritional counselors to help patients change their eating habits for sustainable weight loss, and other staff to help provide safe and effective treatment with the Obalon Balloon System.Dr. Rita Starritt, a treating physician at the Obalon Center for Weight Loss, said, “I am very pleased to be part of the first Obalon Center for Weight Loss. There are so many patients with obesity who want to lose weight but are frustrated by and have failed conventional diet and exercise programs. The Obalon Balloon System is an FDA-approved, scientifically proven, non-surgical weight loss solution for people who are approximately 30 to 100 pounds overweight or have a BMI between 30 and 40. Published results from clinical trials supporting FDA approval showed a strong safety profile and demonstrated that patients receiving the Obalon Balloon System had twice as much weight loss than patients who received a placebo device with diet and exercise therapy.”The Company expects to provide more information on the treatment center strategy in November when it reports third quarter financial results for the quarter ending September 30, 2019.About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics’ business in general, please refer to Obalon Therapeutics’ annual report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2019, Form 10-Q filed with the Securities and Exchange Commission on July 24, 2019, and its future periodic reports filed with the Securities and Exchange Commission.For Obalon Therapeutics, Inc.Investor Contact:
William Plovanic
President & Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.